Serotype‐Specific Dengue Virus IgG Assay Using EDIII‐Based Recombinant Proteins and Its Application in an Endemic Population in Northeast Brazil

Dengue is the most prevalent arboviral disease globally, with Brazil currently experiencing a significant rise in cases. Dengue virus (DENV) typically co-circulates with other clinically and antigenically similar flaviviruses, such as Zika virus (ZIKV). The clinical diagnosis is difficult and accurate serological analysis represents an unmet challenge. Traditionally, serological analysis of DENV infection focuses on the acute phase via detection of NS1 or IgM. Developing IgG DENV-specific assays has been defiant due to the co-circulation of four antigenically distinct serotypes and a strong cross-reactivity with other arboviruses, particularly with ZIKV. The goal of this study was to produce recombinant domain III of the Envelope (EDIII) proteins of each DENV serotype and ZIKV and evaluate the ability to detect specific IgG antibodies. The antigens were tested on the ELISA platform to measure DENV-specific IgG in mice and patients infected with ZIKV and DENV. The assay differentiated serotype-specific IgG responses in susceptible mice (AG129) experimentally infected with DENV or ZIKV. In addition, the test demonstrated a robust performance achieving 87.8% sensitivity and 91.4% specificity when tested against 648 well-characterized sera collected from humans infected with DENV and/or ZIKV. The test was further applied to serum samples collected from 318 healthy individuals from an endemic region in Northwest/Central Brazil, without a previous diagnosis of DENV, and revealed that 65% of the samples reacted with at least one DENV serotype antigen, including 123 monotypic samples (88 for DENV-1) and 90 samples reacting with multiple antigens. Collectively, these results indicate that the IgG DENV-EDIII ELISA is a valuable tool for assessing the serological status of populations in endemic areas, particularly in regions where other flaviviruses, particularly ZIKV, co-circulate and offer support to establish public health policies against the disease.

Authors

Institutions

Publication Details

Journal
Journal of Medical Virology
Published
2024-12-01
DOI
https://doi.org/10.1002/jmv.70100
Citations
4
Primary Topic
Mosquito-borne diseases and control
Type
article
Field-Weighted Citation Impact
2.17
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Serotype‐Specific Dengue Virus IgG Assay Using EDIII‐Based Recombinant Proteins and Its Application in an Endemic Population in Northeast Brazil

Samuel Santos Pereira, Edison Luíz Durigon, Mônica Josiane Rodrigues‐Jesus, Mayanna Moreira Costa Fogaça et al.
4 citations
Journal of Medical Virology
Mosquito-borne diseases and control
2.17
article

Serotype‐Specific Dengue Virus IgG Assay Using EDIII‐Based Recombinant Proteins and Its Application in an Endemic Population in Northeast Brazil

Samuel Santos Pereira, Edison Luíz Durigon, Mônica Josiane Rodrigues‐Jesus, Mayanna Moreira Costa Fogaça, Eduardo Gimenes Martins, Milena Silva Souza, Camila Malta Romano, Jéssica Pires Farias, Jaime Henrique Amorim, Robert Andreata‐Santos, Rafael Rahal Guaragna Machado, Luís Carlos de Souza Ferreira
article en
4 citations

Abstract

Dengue is the most prevalent arboviral disease globally, with Brazil currently experiencing a significant rise in cases. Dengue virus (DENV) typically co-circulates with other clinically and antigenically similar flaviviruses, such as Zika virus (ZIKV). The clinical diagnosis is difficult and accurate serological analysis represents an unmet challenge. Traditionally, serological analysis of DENV infection focuses on the acute phase via detection of NS1 or IgM. Developing IgG DENV-specific assays has been defiant due to the co-circulation of four antigenically distinct serotypes and a strong cross-reactivity with other arboviruses, particularly with ZIKV. The goal of this study was to produce recombinant domain III of the Envelope (EDIII) proteins of each DENV serotype and ZIKV and evaluate the ability to detect specific IgG antibodies. The antigens were tested on the ELISA platform to measure DENV-specific IgG in mice and patients infected with ZIKV and DENV. The assay differentiated serotype-specific IgG responses in susceptible mice (AG129) experimentally infected with DENV or ZIKV. In addition, the test demonstrated a robust performance achieving 87.8% sensitivity and 91.4% specificity when tested against 648 well-characterized sera collected from humans infected with DENV and/or ZIKV. The test was further applied to serum samples collected from 318 healthy individuals from an endemic region in Northwest/Central Brazil, without a previous diagnosis of DENV, and revealed that 65% of the samples reacted with at least one DENV serotype antigen, including 123 monotypic samples (88 for DENV-1) and 90 samples reacting with multiple antigens. Collectively, these results indicate that the IgG DENV-EDIII ELISA is a valuable tool for assessing the serological status of populations in endemic areas, particularly in regions where other flaviviruses, particularly ZIKV, co-circulate and offer support to establish public health policies against the disease.

Journal of Medical VirologyVol. 96(12)
Universidade de São Paulo (BR), Universidade Federal do Oeste da Bahia (BR), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
Good health and well-being
Openalex Percentile: Top 11%
Mosquito-borne diseases and control
2.17
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.